News & Events

• September 25, 2019
  

  Assessment of Long-term Neurodevelopmental Outcome Following Trials of Medicinal Products in Newborn Infants

• September 23, 2019
  

  Development of a Neonatal Adverse Event Severity Scale Through a Delphi Consensus Approach

• September 23, 2019
  Development of a disease progression model for leucine-rich repeat kinase 2 in Parkinson’s disease to inform clinical trial designs

• September 23, 2019
  Enabling efficient use of digital health technologies to support Parkinson’s disease drug development through precompetitive collaboration

• September 20, 2019
  The Qualification of an Enrichment Biomarker for Clinical Trials Targeting Early Stages of Parkinson’s Disease

  Diane Stephensona,∗, Derek Hillb, Jesse M. Cedarbaumc, Maria Tomed, Spiros Vamvakasd, Klaus Romeroa, Daniela J. Conradoa, David T. Dextere, John Seibylf, Danna Jenningsg, Timothy Nicholash, Dawn Matthewsi, Zhiyong Xieh, Syed Imamp, Paul Maguirej, David Russellf, Mark Forrest Gordonk, Glenn T. Stebbinso, Ed Somerl, Jill Gallaghere, Arthur Roache, Peter Bassechesm, Donald Grossetn and Kenneth Marekf on behalf of the Critical Path for Parkinson’s Consortium